We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-17.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$977M
AUM Growth
-$359M
Cap. Flow
-$135M
Cap. Flow %
-13.86%
Top 10 Hldgs %
55.77%
Holding
68
New
11
Increased
16
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.9M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$27.6M
3
BKD icon
Brookdale Senior Living
BKD
+$21.8M
4
AET
Aetna Inc
AET
+$20.5M
5
MOH icon
Molina Healthcare
MOH
+$19.5M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$61.6M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$44M
3
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$38.2M
4
INSM icon
Insmed
INSM
+$25.3M
5
UNH icon
UnitedHealth
UNH
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 77.22%
2 Financials 2.61%
3 Communication Services 2.08%
4 Consumer Staples 1.23%
5 Industrials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
51
Insmed
INSM
$23.3B
– –
-1,391,813
Closed -$25.3M
LAB icon
52
Standard BioTools
LAB
$343M
– –
-32,561
Closed -$352K
PFE icon
53
CALL
Pfizer
PFE
$143B
– –
-1,328,462
Closed -$40.7M
TEVA icon
54
Teva Pharmaceuticals
TEVA
$36.3B
– –
-938,139
Closed -$61.6M
UNH icon
55
UnitedHealth
UNH
$385B
– –
-187,034
Closed -$22M
XBI icon
56
State Street SPDR S&P Biotech ETF
XBI
$10.2B
– –
-4,530
Closed -$317K
KDNY
57
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-2,087
Closed -$294K
GBT
58
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-218,718
Closed -$7.07M
SRRA
59
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-620
Closed -$373K
CSLT
60
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-10,229
Closed -$44K
DPLO
61
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-1,115,902
Closed -$38.2M
WCG
62
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-562,873
Closed -$44M
CASC
63
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-388,550
Closed -$5.17M
ZLTQ
64
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-709,426
Closed -$20.2M
HNT
65
DELISTED
HEALTH NET INC
HNT
– –
-181,029
Closed -$12.4M
TRIV
66
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
– –
-1,462,762
Closed -$9.73M
CELG
67
DELISTED
Celgene Corp
CELG
– –
-10,055
Closed -$1.2M
1 2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2016 Portfolio in Review

As of Q1 2016, Redmile Group held 68 positions worth $977M, down 27% from $1.34B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Redmile Group withdrew a net $135M in Q1 2016, closing 21 positions and reducing 16 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 77% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Redmile Group opened a new position in BioMarin Pharmaceuticals worth $39.4M.

  • Redmile Group's largest Q1 2016 buy was BioMarin Pharmaceuticals: 478,287 shares worth $39.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q1 2016, an estimated $27.6M increase.
  • Redmile Group's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $16.8M.
  • Redmile Group fully exited Teva Pharmaceuticals in Q1 2016, selling an estimated $61.6M.
  • Redmile Group's ten largest holdings make up 56% of its $977M portfolio in Q1 2016.
  • Redmile Group opened 11 new positions and closed 21 in Q1 2016.
  • Redmile Group's portfolio value fell 27% quarter-over-quarter to $977M.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.